How should I transition a patient currently receiving insulin glargine (Lantus) 15 units at 8 am and 35 units at 8 pm to an insulin pump with a basal rate of 31.2 units per day?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Transitioning from Lantus to Insulin Pump Today

Stop the pump basal rate and give 50-80% of the patient's total daily Lantus dose (50 units) as the initial pump basal rate, which equals 25-40 units per day, then restart the pump immediately. Since the patient already has a programmed basal rate of 31.2 units/day on their Mobi pump, this falls appropriately within the recommended range and can be restarted now.

Immediate Transition Protocol

Given that the patient received:

  • 35 units Lantus last night (8 PM)
  • 15 units Lantus this morning (8 AM)
  • Total daily Lantus dose = 50 units

Step-by-Step Approach:

1. Timing Considerations:

  • The morning Lantus dose (15 units at 8 AM) will have peak activity over the next 12-24 hours
  • The evening dose (35 units at 8 PM) still has significant activity remaining
  • There is substantial overlap of both doses currently active

2. Pump Restart Strategy:

Restart the pump immediately with the pre-programmed basal rate of 31.2 units/day 1, 2. This represents approximately 62% of the total daily Lantus dose, which aligns with perioperative guidance suggesting 60-80% of prior basal insulin when transitioning 1.

3. Initial Monitoring and Adjustment:

  • Monitor blood glucose every 2-4 hours for the first 24 hours 3
  • Expect potential overlap hypoglycemia risk for the next 12-18 hours due to residual Lantus activity, particularly from the morning dose
  • Have correction doses of rapid-acting insulin available through the pump bolus function 2
  • Consider temporarily reducing the basal rate by 10-20% (to ~25-28 units/day) for the first 12 hours if glucose trends downward, then return to 31.2 units/day 4

4. Critical Safety Measures:

  • Ensure continuous glucose monitoring (CGM) is active if available with the Control-IQ system 2
  • Prescribe emergency glucagon for hypoglycemia risk during transition 5
  • Patient must be mentally capable and trained to manage the pump independently 6

Rationale for This Approach

The 31.2 units/day basal rate represents a 38% reduction from the total Lantus dose (50 units). This is appropriate because:

  1. Lantus has residual activity: Both doses given in the last 24 hours will continue providing basal coverage for several more hours 7

  2. Pump insulin is more efficient: Continuous subcutaneous insulin infusion (CSII) typically requires 10-20% less total daily insulin than multiple daily injections due to more physiologic delivery 2, 6

  3. The patient's previous pump experience: The 31.2 units/day was their established basal rate, suggesting this dose was previously effective 8

Common Pitfalls to Avoid

  • Do NOT wait until Lantus "wears off" - this creates dangerous gaps in basal coverage and hyperglycemia 1
  • Do NOT use a 1:1 conversion - this will cause hypoglycemia due to overlapping insulin action 9
  • Do NOT restart the pump without adequate patient capability - if the patient cannot self-manage, continue subcutaneous injections with a basal-bolus regimen 1, 6

First 48 Hours Management

Hours 0-12 (Today):

  • Start pump at 31.2 units/day basal
  • Check glucose every 2-4 hours
  • Use pump bolus calculator for meals and corrections
  • Consider temporary basal rate reduction of 10-20% if glucose <120 mg/dL

Hours 12-24 (Tonight):

  • Resume full 31.2 units/day basal rate
  • Continue frequent monitoring
  • Adjust basal rates based on overnight glucose patterns

Hours 24-48 (Tomorrow):

  • Fine-tune basal rates by time of day based on glucose patterns 2
  • Resume normal Control-IQ automated adjustments
  • Return to standard monitoring frequency

If hypoglycemia occurs (<70 mg/dL): Treat immediately with 15g fast-acting carbohydrates, reduce basal rate by 10-20%, and reassess 4, 10

References

Guideline

american association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2023

Guideline

american association of clinical endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2021

Related Questions

Can Toujeo SoloSTAR (insulin glargine U‑300) be substituted for insulin glargine (U‑100)?
What should the basal insulin glargine (Lantus) dose, insulin‑sensitivity factor, and insulin‑to‑carbohydrate ratio be for a 35‑year‑old male, 80 kg, with serum creatinine 1.18 mg/dL (eGFR 87 mL/min/1.73 m²), fasting blood glucose 73 mg/dL while on 32 U nightly Lantus, and current ISF 25 mg/dL per unit and ICR 10 g per unit?
For a 114 kg pregnant woman with diabetes, what is the appropriate starting dose of insulin glargine (Lantus) and how should the basal dose be titrated, including total daily insulin requirement, insulin‑to‑carbohydrate ratio, and correction factor?
Can a 39-year-old male with diabetes who is currently on nightly insulin detemir (Levemir) 34 U be switched to insulin glargine (Lantus), and what dose of Lantus should be used?
How do I convert a patient taking Lantus (insulin glargine) 50 units twice daily to Toujeo (insulin glargine‑U300) dosing?
What is the recommended intravenous morphine dosing schedule every four hours for an opioid‑naïve adult cancer patient with severe pain?
Is a 200 mg dose of trazodone appropriate for treating insomnia?
How quickly will insulin levels rise after stopping weekly 2.4 mg Wegovy (semaglutide)?
How should I manage a 67-year-old patient with occasional dizziness and a Holter monitor showing an asymptomatic 3.9‑second sinus pause who is not taking any heart‑rate‑lowering medications?
Can a transcutaneous electrical nerve stimulation (TENS) unit be used to treat peroneal tendonitis, and what are the recommended settings and precautions?
Does the presence of yeast (Candida) in a pancreatic pseudocyst require antifungal treatment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.